SV1999000052A - Triciclicos substituidos ref. x-12144 - Google Patents

Triciclicos substituidos ref. x-12144

Info

Publication number
SV1999000052A
SV1999000052A SV1999000052A SV1999000052A SV1999000052A SV 1999000052 A SV1999000052 A SV 1999000052A SV 1999000052 A SV1999000052 A SV 1999000052A SV 1999000052 A SV1999000052 A SV 1999000052A SV 1999000052 A SV1999000052 A SV 1999000052A
Authority
SV
El Salvador
Prior art keywords
ref
tricycles
substituted
substituted tricycles
compounds
Prior art date
Application number
SV1999000052A
Other languages
English (en)
Inventor
Nicholas James Bach
Jolie Anne Bastian
Douglas Wade Beight
Qiuping Wang
Michael Dean Kinnick
Michael John Martinelli
Tulio Suarez
Edward David Mihelich
Jr John Michael Morin
Daniel Jon Sall
Jason Scott Sawyer
Thomas Michael Wilson
Edward C R Smith
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of SV1999000052A publication Critical patent/SV1999000052A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/58[b]- or [c]-condensed
    • C07D209/70[b]- or [c]-condensed containing carbocyclic rings other than six-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A UNA CLASE DE NUEVOS COMPUESTOS TRICICLICOS JUNTO CON EL USO DE TALES COMPUESTOS PARA INHIBIR LA LIBERACION DE ACIDOS GRASOS MEDIADA POR sPLA2, PARA EL TRATAMIENTO DE AFECCIONES TALES COMO EL CHOQUE SEPTICO.
SV1999000052A 1998-04-17 1999-04-16 Triciclicos substituidos ref. x-12144 SV1999000052A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6216598A 1998-04-17 1998-04-17

Publications (1)

Publication Number Publication Date
SV1999000052A true SV1999000052A (es) 2000-03-14

Family

ID=22040624

Family Applications (1)

Application Number Title Priority Date Filing Date
SV1999000052A SV1999000052A (es) 1998-04-17 1999-04-16 Triciclicos substituidos ref. x-12144

Country Status (27)

Country Link
EP (2) EP1156050B1 (es)
JP (1) JP4435325B2 (es)
KR (1) KR19990083234A (es)
CN (1) CN1235968A (es)
AR (1) AR018185A1 (es)
AT (2) ATE259818T1 (es)
AU (1) AU757454B2 (es)
BR (1) BR9901275A (es)
CA (1) CA2269256A1 (es)
CO (1) CO5080728A1 (es)
CZ (1) CZ137199A3 (es)
DE (2) DE69914951T2 (es)
EA (1) EA003129B1 (es)
ES (2) ES2213668T3 (es)
HU (1) HUP9901219A1 (es)
ID (1) ID23219A (es)
IL (1) IL129484A0 (es)
NO (1) NO991823L (es)
NZ (1) NZ335252A (es)
PE (1) PE20000472A1 (es)
PL (1) PL332564A1 (es)
SG (1) SG106035A1 (es)
SV (1) SV1999000052A (es)
TR (1) TR199900842A2 (es)
TW (1) TW555760B (es)
YU (1) YU19099A (es)
ZA (1) ZA992773B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999009978A1 (en) * 1997-08-28 1999-03-04 Eli Lilly And Company Method for treatment of non-rheumatoid athritis
WO2001074817A1 (fr) * 2000-03-30 2001-10-11 Yamanouchi Pharmaceutical Co., Ltd. Derives d'hydrazide
CA2413582A1 (en) * 2000-07-14 2002-01-24 Eli Lilly And Company Use of a spla2 inhibitor for the treatment of sepsis
DE60120758T2 (de) * 2000-12-18 2007-05-16 Eli Lilly And Co., Indianapolis Tetracyclische derivate als spla2 inhibitoren
US6933313B2 (en) 2001-03-28 2005-08-23 Eli Lilly And Company Substituted carbazoles as inhibitors of sPLA2
JP2005527464A (ja) * 2001-08-09 2005-09-15 イーライ・リリー・アンド・カンパニー sPLA2インヒビターとしてのシクロヘプタBインドール誘導体
ATE312817T1 (de) 2001-08-09 2005-12-15 Lilly Co Eli Cyclohept'bö indolderivate als spla2-inhibitoren
US6992100B2 (en) 2001-12-06 2006-01-31 Eli Lilly And Company sPLA2 inhibitors
WO2006050007A2 (en) 2004-11-01 2006-05-11 Wyeth Substituted indolizines and derivatives as cns agents
ES2523580T3 (es) 2008-01-11 2014-11-27 Albany Molecular Research, Inc. Piridoindoles substituidos con (1-Azinona)
WO2011003021A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
US8993765B2 (en) 2010-12-21 2015-03-31 Albany Molecular Research, Inc. Tetrahydro-azacarboline MCH-1 antagonists, methods of making, and uses thereof
MX338516B (es) * 2011-04-14 2016-04-20 Actelion Pharmaceuticals Ltd Derivados de acido 7- (heteroaril-amino) -6, 7, 8, 9- tetrahidropirido[1,2-a] indol acetico y sus usos como modulador del receptor de prostaglandina.
PL2825541T3 (pl) 2012-03-16 2016-12-30 Modulatory receptora x wątroby
SI2825542T1 (sl) 2012-03-16 2017-01-31 Vitae Pharmaceutical Inc., Modulatorji jetrnega receptorja X

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3979391A (en) * 1972-11-22 1976-09-07 Sterling Drug Inc. 1,2,3,4-Tetrahydrocarbazoles
PT95692A (pt) * 1989-10-27 1991-09-13 American Home Prod Processo para a preparacao de derivados de acidos indole-,indeno-,piranoindole- e tetra-hidrocarbazole-alcanoicos, ou quais sao uteis como inibidores de pla2 e da lipoxigenase
IL109309A (en) * 1993-04-16 2000-06-29 Lilly Co Eli 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them
IL109311A0 (en) * 1993-04-16 1994-07-31 Lilly Co Eli 1H-indole-3-acetamide sPla2 inhibitors
US6645976B1 (en) * 1994-07-21 2003-11-11 Eli Lilly And Company Indolizine SPLA2inhibitors
CA2240395A1 (en) * 1995-12-13 1997-06-19 David Kent Herron Naphthyl acetamides as spla2 inhibitors
IL129481A0 (en) * 1996-10-30 2000-02-29 Lilly Co Eli Substituted tricyclics
WO1999016453A1 (en) * 1997-09-26 1999-04-08 Eli Lilly And Company Method for the treatment of cystic fibrosis
JP2001522884A (ja) * 1997-11-14 2001-11-20 イーライ・リリー・アンド・カンパニー アルツハイマー病の処置方法

Also Published As

Publication number Publication date
EP1156050A3 (en) 2001-11-28
CZ137199A3 (cs) 1999-11-17
EP0950661B1 (en) 2003-11-12
ES2213668T3 (es) 2004-09-01
ES2210979T3 (es) 2004-07-01
AU757454B2 (en) 2003-02-20
EA199900304A2 (ru) 1999-10-28
ATE254128T1 (de) 2003-11-15
DE69914951D1 (de) 2004-03-25
DE69914951T2 (de) 2004-12-23
EP1156050A2 (en) 2001-11-21
ID23219A (id) 2000-03-30
NO991823L (no) 1999-10-18
NZ335252A (en) 2000-11-24
EP1156050B1 (en) 2004-02-18
BR9901275A (pt) 2000-05-02
JP4435325B2 (ja) 2010-03-17
AU2381899A (en) 1999-10-28
NO991823D0 (no) 1999-04-16
PL332564A1 (en) 1999-10-25
IL129484A0 (en) 2000-02-29
HU9901219D0 (en) 1999-06-28
ZA992773B (en) 2002-07-16
CA2269256A1 (en) 1999-10-17
PE20000472A1 (es) 2000-06-02
TW555760B (en) 2003-10-01
TR199900842A2 (xx) 2000-09-21
DE69912670T2 (de) 2004-08-12
HUP9901219A1 (hu) 2000-08-28
CO5080728A1 (es) 2001-09-25
SG106035A1 (en) 2004-09-30
YU19099A (sh) 2001-09-28
EA199900304A3 (ru) 2000-04-24
JPH11322745A (ja) 1999-11-24
CN1235968A (zh) 1999-11-24
KR19990083234A (ko) 1999-11-25
ATE259818T1 (de) 2004-03-15
EA003129B1 (ru) 2003-02-27
DE69912670D1 (de) 2003-12-18
EP0950661A1 (en) 1999-10-20
AR018185A1 (es) 2001-10-31

Similar Documents

Publication Publication Date Title
SV1999000052A (es) Triciclicos substituidos ref. x-12144
ES2179088T3 (es) Inhibidores de flsa2 1h-indol-3-glioxilamida.
BR9901279A (pt) Triciclicos substituìdos
ECSP12011688A (es) Conjugados de dímeros de pirrolo[1,4]benzodiazepina como agentes anticancerosos
ES2160897T3 (es) Pirazoles como inhibidores de la secretora fosfolipasa a2 humana no pancreatica.
HN1999000015A (es) Tratamiento para una disfuncion sexual femenina
CR6563A (es) Compuestos sustitutos oxoazaheterocyclyl
BR9713261A (pt) Tricìclicos substituìdos
ES2162198T3 (es) Agentes estrogenos.
HN1999000149A (es) Derivados de 4,4-biarilpiperidina
GT200000190A (es) Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas-4-carboxiamino-2-sustituidas.
GT200300201A (es) Nuevas quinazolinonas espirocondensadas y su uso como inhibidores de la fosfodiesterasa
SV2002000249A (es) Derivados de tiazolilamida ref, lea 34082-sv
GT200300187A (es) Compuestos antiinflamatorios de di y trifluoro-triazolo-piridinas
HN1997000098A (es) Ccompuesto de indol 2, 3 sustituido como agentes antiinflamatorios y analgesicos.
GT200500311A (es) Compuestos organicos
ES2159347T3 (es) Naftil-acetamidas como inhibidores de spla2.
SE9901077D0 (sv) Novel use
GT200900287A (es) Extrudidos con enmascaramiento del sabor mejorado
ES2181052T3 (es) Fenilacetamidas como inhibidores de la spla2.
ECSP034531A (es) Derivados sustituidos de c-ciclohexilmetilamina
HN2001000278A (es) Procedimiento para la preparacion de imidazotriazininas substituidas con sulfonamida.
HN2010002683A (es) Compuesto 2-fluoro-11-(piperazin-1-il)dibenzo [b,f][1,4]tiazepina
HN1998000099A (es) Formas de dosificacion de sertralina de liberacion retardada
ES2174034T3 (es) Naftilglioxamidas como inhibidores de spla2

Legal Events

Date Code Title Description
FD Lapse